Centaurus Financial Inc. Buys Shares of 2,227 IQVIA Holdings Inc. (NYSE:IQV)

Centaurus Financial Inc. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,227 shares of the medical research company’s stock, valued at approximately $403,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. increased its stake in shares of IQVIA by 4.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 349,061 shares of the medical research company’s stock valued at $63,227,000 after buying an additional 14,717 shares during the period. Bridgefront Capital LLC acquired a new stake in IQVIA during the third quarter worth approximately $716,000. Toroso Investments LLC grew its stake in IQVIA by 3.5% during the third quarter. Toroso Investments LLC now owns 3,326 shares of the medical research company’s stock worth $602,000 after purchasing an additional 112 shares during the period. Client 1ST Advisory Group LLC grew its stake in IQVIA by 14.0% during the third quarter. Client 1ST Advisory Group LLC now owns 3,507 shares of the medical research company’s stock worth $635,000 after purchasing an additional 430 shares during the period. Finally, B. Riley Wealth Advisors Inc. grew its stake in IQVIA by 7.7% during the third quarter. B. Riley Wealth Advisors Inc. now owns 3,870 shares of the medical research company’s stock worth $702,000 after purchasing an additional 277 shares during the period. Institutional investors and hedge funds own 86.20% of the company’s stock.

IQVIA Stock Down 2.8 %

IQV stock opened at $190.89 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $254.94. The business’s 50 day moving average price is $218.94 and its two-hundred day moving average price is $208.67. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.89 and a current ratio of 0.89. The company has a market capitalization of $35.53 billion, a price-to-earnings ratio of 33.43, a price-to-earnings-growth ratio of 1.92 and a beta of 1.40.

IQVIA (NYSE:IQV – Get Rating) last posted its earnings results on Friday, February 10th. The medical research company reported $2.78 earnings per share for the quarter, topping analysts’ consensus estimates of $2.76 by $0.02. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same quarter in the prior year, the business earned $2.42 EPS. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 9.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the sale, the insider now owns 1,973 shares in the company, valued at approximately $445,128.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at approximately $445,128.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the transaction, the insider now directly owns 17,053 shares in the company, valued at $3,922,190. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on IQV shares. Credit Suisse Group reaffirmed an “outperform” rating and set a $265.00 target price on shares of IQVIA in a research note on Monday, February 13th. StockNews.com initiated coverage on IQVIA in a research report on Thursday. They issued a “hold” rating for the company. JPMorgan Chase & Co. raised their target price on IQVIA from $257.00 to $263.00 and gave the stock an “overweight” rating in a research report on Monday, February 27th. Morgan Stanley lifted their price target on IQVIA from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, February 13th. Finally, Robert W. Baird reduced their price target on IQVIA from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Friday, January 13th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.81.

IQVIA Company Profile

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.